论文部分内容阅读
急性非淋巴细胞型白血病(ANLL)患者加强诱导缓解疗法的几个概念近来被提出来了。作者研究了62例患者,72例次诱导治疗,4种不同的药物联合治疗方案,比较其血液学资料、毒性、预后因素和治疗效应。病人和方法作者报导了从1975年5月至1978年8月共82例ANLL患者。20例由于严重肺炎、其他感染、出血性休克、脑出血、心力衰竭、肠梗阻或变态反应,不用细胞抑制药物治疗。16例年龄在60岁以上。未经化疗的病人在入院后1～18天(中数8天)死亡。61例初治患者接受了四种不同方案的诱导缓解治疗,A方案31例,B方案11例,D方案9例,F方案10例。对11例复发或对包括现在采用的诱导治疗方案之一的其他治疗耐药的复治病人,再给予诱导疗法。
Several concepts for enhancing induction of remission therapy in patients with acute non-lymphoid leukemia (ANLL) have recently been proposed. The authors studied 62 patients, 72 induction therapy, 4 different drug combination regimens, and compared their hematological data, toxicity, prognostic factors and treatment effect. Patients and Methods The authors reported a total of 82 ANLL patients from May 1975 to August 1978. Twenty patients were treated with cytostatics due to severe pneumonia, other infections, hemorrhagic shock, cerebral hemorrhage, heart failure, intestinal blockage or allergy. 16 cases were over 60 years old. Non-chemotherapy patients died 1 to 18 days (median 8 days) after admission. Sixty-one newly-treated patients underwent induction remission with four different regimens: 31 in the A regimen, 11 in the B regimen, 9 in the D regimen and 10 in the F regimen. Induction therapy was given to 11 patients relapsed or to other therapeutically refractory retreatment patients, including one of the currently used induction regimens.